From the Journals

CVD risk continues to fall down to systolic BP of 90 mm HG


 

What is a normal blood pressure?

In an accompanying commentary, Daniel Jones, MD, of the University of Mississippi Medical Center, Jackson, said these new findings support the position that risk imposed by blood pressure level begins well below the current 130/80 mm Hg definition of hypertension and guideline-recommended goal.

The study is “a reminder that even a good execution of treatment of hypertension is far from an ideal way to prevent atherosclerotic cardiovascular disease,” he said.

“A systolic of 130 is not the number we should focus on for patients who are not yet hypertensive, as 130 is not a normal blood pressure,” Dr. Jones added in an audio interview on the JAMA website.

“The findings also suggest that the disease process for atherosclerotic cardiovascular disease begins early in life and support the importance of primordial prevention through a healthy lifestyle, including a healthy diet and levels of physical activity. In addition, the findings highlight the need for a population-based strategy focusing on primordial prevention to reduce the age-related increase in BP reported in all industrialized societies,” Dr. Jones wrote.

He recommended that clinicians encourage a healthy lifestyle in patients and families of patients with cardiovascular disease. “This intervention requires no sophisticated genetic testing or clinical trials to credibly inform a family that the children and grandchildren of a patient with atherosclerotic cardiovascular disease or risk factors will benefit from a healthy lifestyle beginning at the earliest age.

“Clinicians often lose sight of the big picture with regard to blood pressure because they have the patient in front of them. But that patient has children and grandchildren who may share the risk and may be in a better position with regard to prevention of future [coronary artery disease], stroke, and kidney disease,” he said.

Conducting the JAMA audio interview, Clyde Yancy, MD, chief of cardiology at Northwestern University, Chicago, said that “this is very stimulating research. It is not asking the question of what is the target blood pressure for patients with hypertension, but rather: What is the goal blood pressure if you actually want to avoid atherosclerotic cardiovascular disease risk altogether?

“These data have made us understand that there is a difference between the goal blood pressure reduction and treatment thresholds that we respect, the normative blood pressure values we see in a clinical setting, and what is truly normal blood pressure,” Dr. Yancy concluded. “That is a very important nuance, especially when we’re talking about population health. Families and communities need to understand what the true normal is.”

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

COVID-19 cases highlight longstanding racial disparities in health care
MDedge Endocrinology
Evidence suggests possible RAS-blocker benefit in COVID-19 patients
MDedge Endocrinology
ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients
MDedge Endocrinology
Angiotensin drugs and COVID-19: More reassuring data
MDedge Endocrinology
New angiotensin studies in COVID-19 give more reassurance
MDedge Endocrinology
ACE inhibitors and severe COVID-19: Protective in older patients?
MDedge Endocrinology
ARBs didn't raise suicide risk in large VA study
MDedge Endocrinology
Aldosterone-driven hypertension found with unexpected frequency
MDedge Endocrinology
Today’s top news highlights: Addressing racism in maternity care, group forms to protect health professionals from retaliation
MDedge Endocrinology
Renal denervation response similar regardless of CV risks, comorbidities
MDedge Endocrinology